That's a 35% team.
She will school him well. Of course the Rwingers and FAUX will say he won. Hillary will get 57.8% in the general to Donald's 39%. BOOK IT DANO!
The FBI does not prosecute. They investigate. Show some more brilliance.
Greatly increased? Better than average? You are kidding yourself raysfrom98. Listen to something other than right-wing radio and TV. Look up the definition of mainstream.
Cory Renauer: One cancer drug developer I'll be watching closely this year is Celldex Therapeutics (NASDAQ:CLDX). Following the failure of its first drug -- Rintega, meant for treatment of advanced brain cancer -- to undergo a phase 3 trial, the market severely punished this clinical-stage biotech. Rintega performed in line with its earlier trials, but the comparison group receiving standard-of-care outperformed historical averages, and the stock was crushed.
Celldex Therapeutics Antibody Drug Conjugates
IMAGE SOURCE: CELLDEX THERAPEUTICS.
However, Wall Street has ignored the rest of this company's exciting clinical pipeline. It has three separate programs, one of which is in a trial that could support an application in a large, under-served population: triple-negative breast cancer patients.
The indication gets its name because the tumor cells don't express the common targets used in existing therapies. However, a large proportion of the 170,000 triple-negative cases diagnosed worldwide do express a target Celldex's glembatumumab vedotin looks for: gpNMB. In a previous study, a small group of women with advanced triple-negative breast cancer that over-expressed gpNMB receiving glembatumumab went twice as long without disease progression as patients receiving standard therapies.
Glembatumumab is in a larger study designed to support applications for approval in the U.S and EU. The trial's main goal is delaying disease progression, and it could have results by the end of the year, or shortly after, making this one stock you'll want to keep an eye on.
Trump is a yellow haired, yellow bellied piece of trash. Under any civil debating format, he will be brought down to his knees.